0001136261-22-000041.txt : 20220111
0001136261-22-000041.hdr.sgml : 20220111
20220111162732
ACCESSION NUMBER: 0001136261-22-000041
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220110
FILED AS OF DATE: 20220111
DATE AS OF CHANGE: 20220111
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Golembiewski Michael Joseph
CENTRAL INDEX KEY: 0001639479
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22245
FILM NUMBER: 22524196
MAIL ADDRESS:
STREET 1: 7 TURTLE CT
CITY: FLEMINGTON
STATE: NJ
ZIP: 08822
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001017491
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 870449967
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 PARK AVENUE
STREET 2: 2ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (646) 293-2100
MAIL ADDRESS:
STREET 1: 300 PARK AVENUE
STREET 2: 2ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
FORMER COMPANY:
FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC.
DATE OF NAME CHANGE: 20100914
FORMER COMPANY:
FORMER CONFORMED NAME: NEXMED INC
DATE OF NAME CHANGE: 19970311
4
1
ownership.xml
X0306
4
2022-01-10
0
0001017491
SEELOS THERAPEUTICS, INC.
SEEL
0001639479
Golembiewski Michael Joseph
C/O SEELOS THERAPEUTICS, INC.
300 PARK AVENUE, 2ND FLOOR
NEW YORK
NY
10022
0
1
0
0
Chief Financial Officer
Stock Option (right to buy)
1.46
2022-01-10
4
A
0
500000
0.00
A
2032-01-10
Common Stock
500000
500000
D
1/4th of the shares subject to the option shall vest on January 10, 2023, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through such vesting date.
/s/ Michael Golembiewski
2022-01-11